Gabapentin Tablet, Film Coated
Product Images NDC 71335-2765

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2765). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

An illustration showing the formula to calculate Creatinine Clearance (CLCr), which includes variables such as age, weight, serum creatinine, and a correction factor for female patients.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over eight weeks. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. Two lines compare placebo and Gabapentin 3600 mg/day groups during a 4-week dose titration period followed by a 4-week fixed dose period. The Gabapentin group shows a decreasing trend in pain scores over time compared to placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over a 7-week period. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. The graph compares placebo and two Gabapentin doses (1800 mg/day and 2400 mg/day), with pain scores generally decreasing more for Gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar chart depicting the proportion of responders with at least 50% reduction in pain score at endpoint in two controlled PHN studies. Study 1 compares placebo (12%) to Gabapentin 3600 mg (29%). Study 2 compares placebo (14%) to Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is indicated for gabapentin groups versus placebo.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study,' showing the percentage difference on the y-axis and daily dose in milligrams on the x-axis. The chart compares three studies (a, b, c) with plotted points indicating responder rates at various gabapentin doses in patients aged 12 years and older with partial seizures.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin, showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H). This diagram represents the molecular structure of the active ingredient Gabapentin.*

FDA Label Image

Label (Lbl713352765)

Label for Gabapentin Tablets, USP 800 mg, film-coated oral tablets. The label indicates 30 tablets per package. Labeled by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. Includes NDC 71335-2765-1 and storage instructions for controlled room temperature. Barcode and QR codes for package insertion and prescribing information are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.